Non-small cell lung cancer (NSCLC) is one of the most common cancers worldwide. Pulmonary malignancies are the leading cause of death in both men and women1. Treatment generally consists of surgical resection, radiation therapy and/or chemotherapy. Somatic mutations within the kinase domain (exons 18-21) of the epidermal growth factor receptor (EGFR) gene have been reported for 10-35% of NSCLC tumors2, 4, 5. Multiple studies have demonstrated a strong association of EGFR mutation status with response to EGFR tyrosine kinase inhibitors, gefitinib and erlotinib3, 4, 5.
To open a printable assay summary in a new window, click the link below.
(Targeted analysis for 123 cancer hotspot mutations in the EGFR gene by next generation sequencing.)
(in portable document format (pdf) which requires Adobe® Acrobat® Reader™ to view or print; download latest version free)